(株)医学生物学研究所の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証JQS | 医薬品 | 4557/E00978 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2020/05/15 | 日証協 | 99,296株 | -28.66% | 9,100株 | -80.96% | 70,782株 | -26.6% | 13,913株 | +50.61% |
2020/05/08 | 日証協 | 139,196株 | -36.29% | 47,800株 | -76.24% | 96,437株 | -35.34% | 9,238株 | -93.32% |
2020/05/01 | 日証協 | 218,496株 | +112.55% | 201,200株 | +2479.49% | 149,140株 | +221.24% | 138,228株 | +196.35% |
2020/04/24 | 日証協 | 102,796株 | -18.41% | 7,800株 | 0% | 46,427株 | +1.97% | 46,644株 | +5479.43% |
2020/04/17 | 日証協 | 125,996株 | -18.33% | 0株 | -100% | 45,530株 | -38.45% | 836株 | -86.17% |
2020/04/10 | 日証協 | 154,275株 | -17.53% | 7,400株 | -79.93% | 73,976株 | -25.22% | 6,043株 | -87.21% |
2020/04/03 | 日証協 | 187,075株 | -30.76% | 36,875株 | -65.2% | 98,923株 | +6.26% | 47,246株 | -48.03% |
2020/03/27 | 日証協 | 270,200株 | -20.2% | 105,950株 | +71.44% | 93,092株 | -29.03% | 90,906株 | +1277.36% |
2020/03/19 | 日証協 | 338,600株 | +14.28% | 61,800株 | -61.81% | 131,162株 | -3.34% | 6,600株 | -84.19% |
2020/03/13 | 日証協 | 296,300株 | +53.29% | 161,823株 | +163.99% | 135,693株 | -3.21% | 41,742株 | -46.18% |
2020/03/06 | 日証協 | 193,300株 | -17.84% | 61,300株 | +101.78% | 140,196株 | -3.11% | 77,565株 | +174.69% |
2020/02/28 | 日証協 | 235,279株 | -6.05% | 30,379株 | -32.04% | 144,690株 | -7.74% | 28,237株 | -30.48% |
2020/02/21 | 日証協 | 250,421株 | +5.88% | 44,700株 | +8.5% | 156,837株 | +11.98% | 40,620株 | +11.78% |
2020/02/14 | 日証協 | 236,521株 | +10.98% | 41,200株 | -1.72% | 140,053株 | +10.68% | 36,339株 | +3.5% |
2020/02/07 | 日証協 | 213,121株 | -19.7% | 41,921株 | -67.3% | 126,534株 | -12.29% | 35,109株 | -74.04% |
2020/01/31 | 日証協 | 265,421株 | +28.22% | 128,200株 | +49.24% | 144,264株 | +67.81% | 135,238株 | +83.8% |
2020/01/24 | 日証協 | 206,998株 | -40.24% | 85,900株 | +16.08% | 85,970株 | -53.65% | 73,580株 | +0.21% |
2020/01/17 | 日証協 | 346,398株 | -37.79% | 74,000株 | -51.63% | 185,491株 | -43.38% | 73,425株 | -52.6% |
2020/01/10 | 日証協 | 556,821株 | +17.22% | 153,000株 | +2786.79% | 327,590株 | +35.04% | 154,900株 | +6940.91% |
※株式分割は考慮していませんのでご注意ください。
Page Top